RP, XRT, and seeds show similar relapse-free survival

New Orleans-Radical prostatectomy, external beam radiation, and brachytherapy achieve comparable rates of relapse-free survival in patients with localized prostate cancer, according to long-term follow-up data on approximately 1,800 patients treated with one of the three therapeutic modalities.

Related Videos

Related Content

Advertisement

July 10th 2025

FDA grants breakthrough device designation for ArteraAI Prostate tool

Benjamin P. Saylor Hannah Clarke

“This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 10th 2025

EMBARK: Significant OS gains seen with enzalutamide plus leuprolide in nmHSPC

Benjamin P. Saylor

According to the news release, detailed OS data from EMBARK are set to be presented at an upcoming medical conference.

June 19th 2025

Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD

Amy M. Pearlman, MD

The conversation covers practical, case-based strategies for counseling MSM patients.

July 9th 2025

Leva System adds Mayo Clinic overactive bladder content

Benjamin P. Saylor Hannah Clarke

Among the content is additional information on types of urinary incontinence, ways to control urgency, and frequently asked questions about a healthy bladder.

July 9th 2025

Optimizing SNM: PEER trials investigate potential of SNM lead sensing

Colin Goudelocke, MD Hannah Clarke

Colin M. Goudelocke, MD, discusses the PEER trials, which are assessing the safety and efficacy of SNM lead sensing for optimizing SNM programming.

Related Content

Advertisement

July 10th 2025

FDA grants breakthrough device designation for ArteraAI Prostate tool

Benjamin P. Saylor Hannah Clarke

“This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 10th 2025

EMBARK: Significant OS gains seen with enzalutamide plus leuprolide in nmHSPC

Benjamin P. Saylor

According to the news release, detailed OS data from EMBARK are set to be presented at an upcoming medical conference.

June 19th 2025

Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD

Amy M. Pearlman, MD

The conversation covers practical, case-based strategies for counseling MSM patients.

July 9th 2025

Leva System adds Mayo Clinic overactive bladder content

Benjamin P. Saylor Hannah Clarke

Among the content is additional information on types of urinary incontinence, ways to control urgency, and frequently asked questions about a healthy bladder.

July 9th 2025

Optimizing SNM: PEER trials investigate potential of SNM lead sensing

Colin Goudelocke, MD Hannah Clarke

Colin M. Goudelocke, MD, discusses the PEER trials, which are assessing the safety and efficacy of SNM lead sensing for optimizing SNM programming.